Electrophilic fragment screening using native mass spectrometry to identify covalent probes for surface cysteines
Jack W. Klose
A B # , Yezhou Yu A B # , Giovanna Di Trapani B , Kathryn F. Tonissen A B , Louise M. Sternicki A B * and Sally-Ann Poulsen A B *
A
B
Handling Editor: Mibel Aguilar
Abstract
Covalent chemical probes form a covalent bond with a target protein of interest to elicit an effect and methods to identify and characterise them are needed. We developed a native mass spectrometry (nMS) method to screen an electrophilic covalent fragment library and identified specific novel binders for the surface exposed cysteine residues of carbonic anhydrase III (CA III). The nMS method was extended to determine the site of protein modification and measure simultaneous binding of an active site noncovalent inhibitor and covalent fragment hit, which is not possible with intact denaturing MS. This study demonstrates the utility of using nMS and the advantages when compared to intact denaturing MS for the discovery and characterisation of new covalent ligands.
Keywords: acrylamide, carbonic anhydrase, carbonic anhydrase inhibitor, chloroacetamide, covalent drug discovery, cysteine, electrophilic fragments, fragment based drug discovery, native mass spectrometry, thiocyanate.
References
1 Boike L, Henning NJ, Nomura DK. Advances in covalent drug discovery. Nat Rev Drug Discov 2022; 21(12): 881-898.
| Crossref | Google Scholar | PubMed |
2 Dalton SE, Di Pietro O, Hennessy E. A medicinal chemistry perspective on FDA-approved small molecule drugs with a covalent mechanism of action. J Med Chem 2025; 68(3): 2307-2313.
| Crossref | Google Scholar | PubMed |
3 Guo Y, shuai W, Tong A, Wang Y. Advanced technologies for screening and identifying covalent inhibitors. Trends Anal Chem 2024; 178: 117833.
| Crossref | Google Scholar |
4 Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020; 19(8): 533-552.
| Crossref | Google Scholar | PubMed |
5 Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019; 575(7781): 217-223.
| Crossref | Google Scholar | PubMed |
6 Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem 2020; 63(1): 52-65.
| Crossref | Google Scholar | PubMed |
7 Mahran R, Kapp JN, Valtonen S, Champagne A, Ning J, Gillette W, Stephen AG, Hao F, Plückthun A, Härmä H, et al. Beyond KRAS(G12C): biochemical and computational characterization of sotorasib and adagrasib binding specificity and the critical role of H95 and Y96. ACS Chem Biol 2024; 19(10): 2152-2164.
| Crossref | Google Scholar | PubMed |
8 Dhillon S. Adagrasib: first approval. Drugs 2023; 83(3): 275-285.
| Crossref | Google Scholar | PubMed |
9 Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022; 386(15): 1397-1408.
| Crossref | Google Scholar | PubMed |
10 Blair HA. Ritlecitinib: first approval. Drugs 2023; 83(14): 1315-1321.
| Crossref | Google Scholar | PubMed |
11 Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, Nguyen C, Everley RA, Trujillo JI, Johnson DS, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol 2019; 14(6): 1235-1242.
| Crossref | Google Scholar | PubMed |
12 Xu W, Kang C. Fragment-based drug design: from then until now, and toward the future. J Med Chem 2025; 68(5): 5000-5004.
| Crossref | Google Scholar | PubMed |
13 Resnick E, Bradley A, Gan J, Douangamath A, Krojer T, Sethi R, Geurink PP, Aimon A, Amitai G, Bellini D, et al. Rapid covalent-probe discovery by electrophile-fragment screening. J Am Chem Soc 2019; 141(22): 8951-8968.
| Crossref | Google Scholar | PubMed |
14 Wang G, Seidler NJ, Röhm S, Pan Y, Liang XJ, Haarer L, Berger B-T, Sivashanmugam SA, Wydra VR, Forster M, et al. Probing the protein kinases′ cysteinome by covalent fragments. Angew Chem Int Ed 2025; 64(8): e202419736.
| Crossref | Google Scholar | PubMed |
15 Keeley A, Ábrányi-Balogh P, Keserű GM. Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors. MedChemComm 2019; 10(2): 263-267.
| Crossref | Google Scholar | PubMed |
16 Edwards AN, Hsu K-L. Emerging opportunities for intact and native protein analysis using chemical proteomics. Analytica Chimica Acta 2025; 1338: 343551.
| Crossref | Google Scholar | PubMed |
17 Sternicki LM, Poulsen SA. Fragment-based drug discovery campaigns guided by native mass spectrometry. RSC Med Chem 2024; 15(7): 2270-2285.
| Crossref | Google Scholar | PubMed |
18 Sternicki LM, Poulsen S-A. Toward routine utilisation of native mass spectrometry as an enabler of contemporary drug development. RSC Med Chem 2025; [Published online early, 30 July 2025].
| Crossref | Google Scholar |
19 Poulsen S-A. Fragment screening by native state mass spectrometry. Aust J Chem 2013; 66(12): 1495-1501.
| Crossref | Google Scholar |
20 Yu Y, Sternicki LM, Hilko DH, Jarrott RJ, Di Trapani G, Tonissen KF, Poulsen S-A. Investigating active site binding of ligands to high and low activity carbonic anhydrase enzymes using native mass spectrometry. J Med Chem 2024; 67(17): 15862-15872.
| Crossref | Google Scholar | PubMed |
21 Poulsen S-A, Davis RA, Keys TG. Screening a natural product-based combinatorial library using FTICR mass spectrometry. Bioorg & Med Chem 2006; 14(2): 510-515.
| Crossref | Google Scholar | PubMed |
22 Gavriilidou AFM, Holding FP, Coyle JE, Zenobi R. Application of native ESI-MS to characterize interactions between compounds derived from fragment-based discovery campaigns and two pharmaceutically relevant proteins. SLAS Discov 2018; 23(9): 951-959.
| Crossref | Google Scholar | PubMed |
23 Peschke M, Verkerk UH, Kebarle P. Features of the ESI mechanism that affect the observation of multiply charged noncovalent protein complexes and the determination of the association constant by the titration method. J Am Soc Mass Spectrom 2004; 15(10): 1424-1434.
| Crossref | Google Scholar | PubMed |
24 Mehmood S, Allison TM, Robinson CV. Mass spectrometry of protein complexes: from origins to applications. Annu Rev Phys Chem 2015; 66: 453-474.
| Crossref | Google Scholar | PubMed |
25 Kitova EN, El-Hawiet A, Schnier PD, Klassen JS. Reliable determinations of protein–ligand interactions by direct ESI-MS measurements. Are we there yet? J Am Soc Mass Spectrom 2012; 23(3): 431-441.
| Crossref | Google Scholar | PubMed |
26 Boeri Erba E, Barylyuk K, Yang Y, Zenobi R. Quantifying protein–protein interactions within noncovalent complexes using electrospray ionization mass spectrometry. Anal Chem 2011; 83(24): 9251-9259.
| Crossref | Google Scholar | PubMed |
27 Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: Carbonic anhydrase, its inhibition and activation. Bioorg & Med Chem Lett 2023; 93: 129411.
| Crossref | Google Scholar | PubMed |
28 Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg & Med Chem 2007; 15(23): 7229-7236.
| Crossref | Google Scholar | PubMed |
29 Silagi ES, Batista P, Shapiro IM, Risbud MV. Expression of carbonic anhydrase III, a nucleus pulposus phenotypic marker, is hypoxia-responsive and confers protection from oxidative stress-induced cell death. Scientific Reports 2018; 8(1): 4856.
| Crossref | Google Scholar | PubMed |
30 Chai YC, Jung CH, Lii CK, Ashraf SS, Hendrich S, Wolf B, Sies H, Thomas JA. Identification of an abundant S-thiolated rat liver protein as carbonic anhydrase III; characterization of S-thiolation and dethiolation reactions. Arch Biochem Biophys 1991; 284(2): 270-278.
| Crossref | Google Scholar | PubMed |
31 Tu C, Chen X, Ren X, LoGrasso PV, Jewell DA, Laipis PJ, Silverman DN. Interactions of active-site residues and catalytic activity of human carbonic anhydrase III. J Biol Chem 1994; 269(37): 23002-23006.
| Google Scholar | PubMed |
32 Pace NJ, Weerapana E. Diverse functional roles of reactive cysteines. ACS Chem Biol 2013; 8(2): 283-296.
| Crossref | Google Scholar | PubMed |
33 Go YM, Chandler JD, Jones DP. The cysteine proteome. Free Radic Biol Med 2015; 84: 227-245.
| Crossref | Google Scholar | PubMed |
34 Yu Y, Poulsen S-A, Di Trapani G, Tonissen KF. Exploring the redox and pH dimension of carbonic anhydrases in cancer: a focus on carbonic anhydrase 3. Antioxid Redox Signal 2024; 41(13–15): 957-975.
| Crossref | Google Scholar | PubMed |
35 Thomas RP, Heap RE, Zappacosta F, Grant EK, Pogány P, Besley S, Fallon DJ, Hann MM, House D, Tomkinson NCO, et al. A direct-to-biology high-throughput chemistry approach to reactive fragment screening. Chem Sci 2021; 12(36): 12098-12106.
| Crossref | Google Scholar |
36 Glöckner S, Heine A, Klebe G. A proof-of-concept fragment screening of a hit-validated 96-compounds library against human carbonic anhydrase II. Biomolecules 2020; 10(4): 518.
| Crossref | Google Scholar | PubMed |
37 Del Giudice R, Monti DM, Truppo E, Arciello A, Supuran CT, De Simone G, Monti SM. Human carbonic anhydrase VII protects cells from oxidative damage. Biol Chem 2013; 394(10): 1343-1348.
| Crossref | Google Scholar | PubMed |
38 Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, Nabet B, He S, Resnick E, Rogel A, et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat Chem Biol 2021; 17(9): 954-963.
| Crossref | Google Scholar | PubMed |
39 Ghebremariam YT, Erlanson DA, Cooke JP. A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J Pharmacol Exp Ther 2014; 348(1): 69-76.
| Crossref | Google Scholar | PubMed |
40 Gehringer M, Laufer SA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem 2019; 62(12): 5673-5724.
| Crossref | Google Scholar | PubMed |
41 Craven GB, Affron DP, Kösel T, Wong TLM, Jukes ZH, Liu CT, Morgan RML, Armstrong A, Mann DJ. Multiparameter kinetic analysis for covalent fragment optimization by using quantitative irreversible tethering (qIT). Chembiochem 2020; 21(23): 3417-3422.
| Crossref | Google Scholar | PubMed |
42 Shannon DA, Weerapana E. Covalent protein modification: the current landscape of residue-specific electrophiles. Curr Opin Chem Biol 2015; 24: 18-26.
| Crossref | Google Scholar | PubMed |
43 Enamine. Electrophilic Covalent Probe Library. Available at https://enamine.net/compound-libraries/covalent-libraries/electrophilic-covalent-probe-library [Verified 23 April 2025]
44 Moeker J, Mahon BP, Bornaghi LF, Vullo D, Supuran CT, McKenna R, Poulsen S-A. Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates. J Med Chem 2014; 57(20): 8635-8645.
| Crossref | Google Scholar | PubMed |
45 Mujumdar P, Teruya K, Tonissen KF, Vullo D, Supuran CT, Peat TS, Poulsen S-A. An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition, and protein X-ray structures of psammaplin C. J Med Chem 2016; 59(11): 5462-5470.
| Crossref | Google Scholar | PubMed |
46 García-Nafría J, Watson JF, Greger IH. IVA cloning: a single-tube universal cloning system exploiting bacterial in vivo assembly. Scientific Reports 2016; 6(1): 27459.
| Crossref | Google Scholar | PubMed |
47 Simpson M, Poulsen S-A. An overview of Australia’s compound management facility: the Queensland Compound Library. ACS Chem Biol 2014; 9(1): 28-33.
| Crossref | Google Scholar | PubMed |
48 Marty MT. A universal score for deconvolution of intact protein and native electrospray mass spectra. Anal Chem 2020; 92(6): 4395-4401.
| Crossref | Google Scholar | PubMed |
